We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk myelodysplastic syndromes. We will then report a study testing the efficacy and safety of imetelstat, a new telomerase-inhibitor, in the treatment of patients with lower-risk MDS and anemia following ESA failure. We will then review an interesting therapeutic approach to improve or restore erythroid response by adding lenalidomide to MDS patients treated with erythropoietin but lost the response. Finally, we will return to the “hot” topic of targeting the TP53 mutation, by summarizing an important clinical trial using a TP53 activator.
The topics and papers to be discussed:
- Venetoclax and HMA for HR-MDS
- Imtetelstat for LR-MDS
- EPO vs EPO and Len
- APR + vidaza for TP53 mutation HR-MDS
- https://ascopubs.org/doi/full/10.1200/JCO.20.02342; https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V15.6.9077/463080/Targeting-TP53-Mutations-in-Myelodysplastic